Posts by MacD


DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms

Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 – DCprime, the front-runner in the field of relapse vaccines, and Glycotope GmbH, a clinical-stage oncology/immuno-oncology company built on world-leading glycobiology expertise, today announced an expansion of their existing partnership through a new research collaboration and licensing agreement. Originally initiated in July 2018, the partnership combines


DCprime and PCI Biotech Announce a Research Collaboration to Explore Novel Cancer Vaccination Concepts

Leiden, The Netherlands and Oslo, Norway, September, 1st 2020 – DCprime, the front-runner in the field of relapse vaccines, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation, today announced an extensive research collaboration. Within the collaboration, DCprime and PCI Biotech will combine their know-how and


DCprime Extends International Roll-out of DCP-001 Into the United States

Opening of IND follows approval to study DCP-001 in multiple European countries Leiden, The Netherlands, May 13, 2020 –DCprime, the front-runner in the field of relapse vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for DCP-001, an allogeneic cancer relapse vaccine currently being


DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia

Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse


DCprime to Present Long-term Follow-up and Survival Data for Lead Relapse Vaccine Candidate DCP-001 in High-Risk AML and MDS Patients

Presentation at ASH Annual Meeting Shows Potential to Prolong Relapse-Free Survival and Overall Survival Using an Allogeneic Cell-based Vaccine in the Post-Remission Setting Leiden, The Netherlands, November 13, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of updated clinical results for its lead product DCP-001 at the upcoming 61st